BiotechTube
Empros Pharma

Empros Pharma

Stockholm, Sweden· Est.
emprospharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.8M

Overview

Empros Pharma is a private, clinical-stage biotech developing EMP16, an oral combination therapy for weight-loss maintenance in obesity. The company, founded by Uppsala University researchers and Flerie Invest, has reported positive Phase 2 topline results (POEM study). It operates with a small, experienced team and a science-driven culture, aiming to address a significant gap in the current obesity treatment landscape.

ObesityMetabolic Disease

Technology Platform

Oral drug delivery platform focused on delaying food digestion and absorption using fixed-dose combinations of approved compounds.

Funding History

1
Total raised:$3.8M
Seed$3.8M

Opportunities

Targeting the large and growing unmet need for long-term weight-loss maintenance therapies, a key gap in the current obesity treatment landscape.
An effective oral therapy could see high adoption due to greater convenience and patient preference compared to injectables.

Risk Factors

High clinical development risk associated with advancing to Phase 3 trials.
Significant financing risk as a private, pre-revenue company needing capital for expensive late-stage studies.
Intense competition from large pharma companies with substantial resources in the obesity market.

Competitive Landscape

Operates in the highly competitive obesity pharmacotherapy market, competing against large players like Novo Nordisk and Eli Lilly. Its differentiation is an oral therapy focused on the maintenance phase, whereas current leading drugs are injectables primarily for weight loss induction.

More companies in Sweden →